Medicare Program: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

Research!America, a nonprofit alliance advocating for science and innovation, opposes the proposal to treat fixed-dose combination products as single-source drugs. They argue that such a policy could discourage research into making treatments more convenient and accessible for patients, such as moving from intravenous to subcutaneous injections.

The commenter, writing as a healthcare consumer and advocate, opposes the proposed rule for the Medicare Drug Price Negotiation Program. They argue that the rule penalizes patient-friendly drug improvements, places undue administrative burdens on neighborhood pharmacies, and establishes permanent regulations before the long-term impacts of the negotiations are understood.